Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Imvision Therapeutics Inc. - Exhibit 10.7

EXHIBIT 10.7

 

 

AGREEMENT

Strain Development, Process Development and
Manufacturing of Clinical Grade Material of a Fel d1 MAT Fusion Protein 

 

 

between

 

ImVisioN GmbH, Feodor Lynen Strasse 5, Hannover

(IVN)

 

and

 

Strathmann Biotec AG, Habichthorst 30, 22459 Hamburg,
Germany

(SBAG)

1

Preamble

ImVisioN GmbH is a biotechnology company based in Hannover,
Germany, and focused on the development of novel immuntherapies based on its MAT
(Modular-Antigen-Transporter) technology platform to treat allergic diseases,
(chronic) infectious diseases and possibly cancer.

ImVisioN has acquired from BioVisioN AG the IP portfolio
covering the MAT technology platform. Furthermore, ImVisioN has obtained an
exclusive license to a patent application (Grönlund et. al, 2003) covering the
recombinant expression of the major cat dander allergen Fel d1 in native
conformation, which comprises the allergen module in ImVisioN’s lead product
IVN201.

The Company’s lead product, IVN201, an immunotherapeutic to
treat cat dander allergy is currently undergoing preclinical development and is
expected to enter clinical trials in early 2006. Therefore, first human
proof-of-concept is projected for early 2007.

SBAG is a GMP contract manufacturing organization which has
long-lasting experience in GMP manufacture, especially in production of
recombinant proteins derived from Escherichia coli (E. coli). 

The overall project is divided in 3 project phases. In a first
phase a production strain for manufacturing of Fel d1 MAT Fusion Protein will be
established using SBAG’s technology. In a second phase this production strain
will be used to establish a process for production of Fel d1 MAT Fusion Protein.
The process consists of a fermentation process, if necessary isolation and
refolding of the protein from inclusionbodies, and a down stream process for
purification of Fel d1 fusion protein. In a third phase the process will be
transferred to SBAG’s GMP facility in Hannover for manufacturing Fel d1 MAT
fusion protein under GMP conditions.

Now, therefore in consideration of the foregoing and of the
mutual representations, warranties and covenants contained in this Agreement and
other good and valuable considerations the Parties hereby agree as follows: 

2

	
1. 		
Obligations of SBAG:

	

	
1.1 		
In a first phase, SBAG will establish a production strain for manufacturing of Fel d1 MAT Fusion Protein. Starting material for strain development is strain M15 (pREP4/pQE30), which was originally established in Prof.
Crameri’s laboratories at the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos. SBAG will use this strain for preparation of plasmid DNA coding for the Feld1 fusion protein. This plasmid is used as a template for synthesis of a
modified cDNA sequence coding for Fel d1 MAT Fusion Protein (without His Tag) via PCR. Optionally cDNAs can be produced by chemical synthesis. PCR products are cloned into SBAG’s expression plasmids (heat inducible and IPTG inducible). Both
expression plasmids are transformed into 3 different E.coli strains. Resulting strains are tested for expression via induction by 42°C and IPTG, respectively. Analysis of expression is carried out by SDS-PAGE and Coomassie staining. The aim of
the first phase is to establish a well characterised E.coli production strain, which expresses the Feld1 MAT Fusion protein without the original C-terminal His-Tag. All materials used for establishment should be free of compounds derived from animal
origin. SBAG’s E.coli strains are characterised by Certificates of Analysis (C of As). If other E.coli stains are used, SBAG can not guarantee for the origin and documentation of these strains. In this case INV and SBAG should discuss in good
faith and agree on a supplier who delivers a suitable strain and documentation. SBAG will document the establishment and the selection of the strain by a Strain Development Report. SBAG will recommend one strain for further development work. INV has
to agree on the recommended strain or may select another strain, in any case on it’s own resposibility.

	
	 	 
		
If a production strain can not be established by SBAG’s routine procedure as described above, both parties shall discuss in good faith the scope and the costs of the additional working hours.

	
	 	 
	
1.2 		
In the second phase the production strain (see1.1) will be used to establish a process for production of Fel d1 MAT Fusion Protein. The selected strain will be used for establishment of a Research Cell Bank (RCB) and in parallel
for manufacturing of a Master Cell Bank (MCB) and a Working Cell Bank (WCB). The RCB is not further characterized and will be used as a starting material for process development until the WCB is manufactured and released. The WCB is the starting
material for all

	

 3

further development work. MCB and WCB
are manufactured and tested under GMP conditions at SBAG’s pilot plant in
Hannover, Feodor Lynen Strasse 5. SBAG should produce 200 vials of MCB and 200
vials of WCB. Manufacturing will be performed in cleanroom category A in B. Both
cell banks will be stored in the vapour phase of liquid nitrogen. Testing
methods and specifications are outlined in Appendix I. Both cell banks are
released by SBAG’s Head of Quality Control. The documentation package contains a
C of A, manufacturing reports, quality report as well as a list of raw
materials.

Process development will be performed
at SBAG’s facilities in Hamburg, Habichthorst 30. In a first step a fermentation
protocol has to be established. Media adaptation, if necessary, is performed by
shaking flask experiments. All other development steps are performed at 10 L
fermentation scale: e.g.: growth characteristics, product formation, induction
time and harvesting point. Goal of the fermentation process development is a
reproducible batch fermentation process with complex media, free of animal
derived compounds and to produce biomass for further development. The number of
fermentation runs is limited to a maximum number of 10 runs. SBAG should make
best efforts to use not more than 10 fermentations. Only the actually performed
fermentations will be invoiced to IVN. If additional fermentation runs are
necessary both parties shall discuss and agree in good faith the scope and costs
of the additional runs.

If the protein is expressed as
insoluble inclusion bodies, a refolding strategy has to be established. This
package includes lysis of cells, isolation and purification of inclusionbodies,
solubilisation and refolding of the protein as well as clarification
(filtration) of the protein solution. 

The working package is limited to 480
working hours. SBAG should make best efforts to use not more than 480 hours.
Only the actually used hours are invoiced to IVN. If additional working hours
are necessary both parties shall discuss and agree in good faith the scope and
costs of the additional hours.

SBAG will establish a reproducible and
scalable downstream process (DSP). Specifications for purity and yields are
unknown today. Therefor the parties agree to discuss and agree on the
specifications and yields, during the performance of the services as soon as
sufficient data are available. SBAG will establish the DSP at small scale. Upon
agreement in writing of both parties, this process will be scaled up 

4

		
to a scale which allows processing of biomass from a 10 L fermentation. SBAG will not use any compounds derived from animal origin and SBAG will only use chromatography resins with available Regulatory Support Files (RSF). The
working package is limited to 1200 working hours. SBAG should make best efforts to use not more than 1200 hours. Only the actually used hours are invoiced to IVN. If additional working hours are necessary both parties shall discuss in good faith the
scope of the additional hours.

	
	 	 
		
SBAG will document the development work by three development reports for fermentation development, isolation of inclusionbodies and refolding as well as development of a downstream process.

	
	 	 
	
1.3 		
Manufacturing under GMP conditions

	
	 	 
		
Process development is completed at 10 L scale. In a third phase the process will be transferred 1:1 to SBAG’s pilot plant in Hannover, Feodor-Lynen Strasse 5. One complete process will be manufactured in SBAG’s Hannover
facilities and equipment. Goal of the Tech Transfer is to establish the process, which was developed under R&D conditions in an GMP environment. Analytical data from in- process-controls as well as analytical data from the product are compared
with data from the development phase. Tech Transfer is documented by a Tech Transfer report. Results from analytical testing will show, if the process is reproducible under the Hannover conditions or if further adaptation/optimisation is needed. The
parties agree, that if the Tech transfer run is comparable to the runs performed in Hamburg one additional run is sufficient to show reproducibility of the process. If further adaptation/optimisation is necessary a third 10 L run should be
performed. The parties will discuss the results after each run and decide mutually if additional runs are needed. Fel d1 MAT Fusion Protein from these runs (if the quality is sufficient) will be delivered to IVN for formulation/stability studies and
preclinical studies.

	
	 	 
		
If reproducibility is demonstrated SBAG will manufacture one 10 L batch under GMP conditions. Any further batch requested by IVN shall be ordered and invoiced separately from this Agreement. SBAG will manufacture drug substance as
liquid concentrate bulk. Manufacturing is performed according to the batch manufacturing record. Testing will be done according to 1.4. The bulk material will be released by SBAG’s head of quality control. IVN will receive the following
documentation: executed batch manufacturing record, C of A , quality report.

	

5 

	1.4 	
      Analytical testing

	 	 
		
      Analytical testing will be performed for
      in-process-controls and for release testing. In the table outlined in
      Appendix II are the analytical testing methods suggested by SBAG. Most of
      the testing will be conducted by SBAG. Sterility and endotoxin testing
      will be conducted by L&S. Peptide mapping and N-terminal sequencing
      will be conducted by Biovision (Hannover) after inspection and acceptance
      by SBAG. The scope of analytical testing below includes the set up of the
      testing procedures and performance of all measurements by SBAG to be
      performed under this agreement. Validation procedures are not included.
      The testing methods will be discussed and agreed upon by SBAG and IVN
      prior to the commencement of testing. Stability testing and
      characterization of a reference standard are not included in the scope of
      work.

	 	 
		
      IVN will receive testing instruction for methods
      performed by SBAG.

	 	 
	2. 	
      Responsibilities of IVN:

	 	 
	2.1 	
      IVN will provide SBAG with all necessary information and
      documentation on the Fel d1 MAT Fusion Protein cDNA sequence and the
      corresponding Fel d1 MAT Fusion Protein. IVN will assist SBAG in solving
      technical problems caused by the properties of the Fel d1 MAT Fusion
      Protein.

	 	 
	2.2 	
      IVN will notify SBAG in writing if IVN approves the
      documentation sent by SBAG (SBAG Documentation) within 2 weeks after its
      receipt. In case IVN does not give approval to the SBAG documentation and
      requests amendments or additional information to be included, IVN shall
      request those changes and additional information in writing within 2 weeks
      after receipt of the SBAG Documentation and SBAG will include said changes
      and additional information in the SBAG Documentation within 3 weeks after
      receipt of such request from IVN.

	 	 
	2.3 	
      IVN will provide an anti Feld1 antibody for establishment
      of a Western Blot method. IVN will further provide His tagged Fel d1
      Fusion protein and original expression strains as reference material if
      requested by SBAG.

	 	 
	2.4 	
      IVN hereby grants to SBAG a non-exclusive license for use
      of its necessary proprietary technologies, know-how and materials for the
      sole purpose of SBAG’s performance of the Services in accordance with this
      Agreement.

6

	3. 	
      Payments

	 	 
	3.1. 	
      Subject to SBAG`s performance of services in accordance
      with this Agreement, IVN shall pay to SBAG a total amount of 767.000,-
      EUR.

	 	 
	3.2. 	
      SBAG will invoice IVN after completion of each milestone
      and acceptance of documentation by IVN. Milestones are defined in Appendix
      III. All payments provided in this Agreement have to be made to the
      following account:

	 	Account-No. 	########
	 	Bank 	Deutsche Bank Hamburg 
	 	Bank-No. 	200700 00

		
      Each payment has to be made free of charges and plus VAT
      if the payment is subject to VAT according to the applicable
law.

	 	 
	3.3. 	
      Material costs for chromatography resins, chromatography
      columns, filter cartridges, ultrafiltration/diafiltration (UF/DF)
      membranes, disposable bags, disposable tubings and tubing connections will
      be charged separately with 5% overhead. The cost of such materials and
      supplies shall not exceed 20.000 EUR, unless approved in writing by
      IVN.

	 	 
	3.4 	
      All Payments shall be made by IVN within thirty (30) days
      after the date of IVN`s receipt of the invoice from SBAG by IVN.

	 	 
	4. 	
      Delimination of pharmaceutical
    responsibilities

	 	 
		
      Each party’s responsibility in the manufacturing and
      testing process of Fel d1 MAT Fusion Protein are agreed upon in Appendix
      IV.

	5. 	
      Transport

	 	 
	5.1 	
      IVN will be responsible for selecting the carrier and
      making all claims with carriers, insurers, warehouseman and others for
      wrong delivery, non-delivery, loss, damage or delay of the deliverables to
      be send by SBAG to IVN.

	 	 
	5.2 	
      Fel d1 MAT Fusion Protein shall be packaged and prepared
      for shipment by SBAG.

	 	 
	5.3 	
      Title to and risk of loss to all deliverables such as but
      not limited to Fel d1 MAT Fusion Protein shipped by SBAG shall pass from
      SBAG to IVN after the handing- over of the deliverables to the
    carrier.

7

	
6. 		
Indemnification:

	
	 	 
		
The parties depart from the idea that manufacturing of Fel d1 MAT Fusion Protein does not infringe any third parties intellectual property rights.

	
	 	 
		
IVN shall defend, at its expense, SBAG, its directors, officers, employees, and agents, against all claims, demands, actions or proceedings brought against SBAG by third parties based on the alleged or actual infringement of
intellectual property rights owned or controlled by such third party by the manufacture, use or sale of the Product as instructed by IVN ("Claim"). IVN will pay for any liability, damage, loss or expenses (including reasonable attorneys’ fees
and court costs) incurred or imposed upon the SBAG, attributable to such Claim that result from a settlement or are awarded in a final judgment against the SBAG, provided that the SBAG shall: (i) promptly notify IVN in writing of the Claim; (ii)
grant IVN sole control of the defence and settlement of the Claim; and (iii) provide IVN with all assistance, information and authority required for the defence and settlement of the Claim. IVN may participate in proceedings on the Claim, provided
that such participation and representation is at its own expense.

	
	 	 
	
7. 		
Liability

	
	 	 
	
7.1 		
Limitation of liability:

	
	 	 
		
Except as provided elsewhere in this Agreement, neither party shall be liable to the other, subcontractors or affiliates for indirect, incidental, special or consequential damages arising out of any of the terms and conditions of
this Agreement with respect to its or their performance hereunder.

	
	 	 
	
7.2 		
Liability Cap

	
	 	 
		
Not withstanding anything to the contrary, the aggregate liability, barring insurance payments, of SBAG under this Agreement to any and all claims arising out of this Agreement shall in no event exceed the amount stated in article
3.1.

	
	 	 
	
8. 		
Confidentiality

	
	 	 
		
Both parties agree to keep any Confidential Information (as defined below) of the other party confidential, using methods at least as stringent as each party uses to protect its own confidential information. "Confidential
Information" shall include parties' collaborative development plan and development reports, inventions and

	

8 

unpublished patent applications within
the scope of IVN Intellectual Property and SBAG Intellectual Property as set
forth in Section 9 and all information concerning the disclosing party and any
other information marked in writing by the disclosing party as confidential or
accompanied by correspondence of the disclosing party indicating such
information is confidentially exchanged between the parties hereto. Except as
provided in this agreement or upon authorisation in advance in writing by the
discloser, the Recipient shall grant access to the Confidential Information only
to its own employees who are involved in the performance of this Agreement and
need to know such Confidential Information and the recipient shall require such
employees to be bound by this agreement as well. The confidentiality and use
obligations set forth above apply to all or any part of the confidential
information disclosed hereunder except to the extent that:

	 	(i) 	
      SBAG or IVN can show by written record that it possessed
      the information prior to its receipt from the other party;

	 	 	 
	 	(ii) 	
      the information was already available to the public or
      became so through no fault of SBAG or IVN;

	 	 	 
	 	(iii) 	
      the information is subsequently disclosed to SBAG or IVN
      by a third party that has the right to disclose it free of any obligations
      of confidentiality; or

	 	 	 
	 	(iv) 	
      five (5) years have elapsed from the expiration of this
      agreement except if the Confidential Information is still subject to
      confidentiality as provided for by the laws of a country in the
      territory.

	9. 	 Inventions

	 	 
	9.1 	 If inventions are made in connection with the development
        of the Fel d1 Fusion protein manufacturing process for the production
        of the Fel d1 Fusion Protein such inventions shall, in principle, be assigned
        to IVN and SBAG together as joined owners, if not provided otherwise hereinafter.
        The following principles shall apply to this agreement:

	 	 
	 		
          The industrial and intellectual property rights
            relating to Fel d1 Fusion Protein as a substance, including all derivatives
            and other modifications or the use of Fel d1 Fusion Protein shall
            exclusively be assigned to IVN (“IVN Intellectual Property”).
          

        

9

 

	 		
          In the event demonstrated by SBAG that the invention
            can be applied not only in the production of Fel d1 Fusion Protein
            but also in the production of other substances, SBAG shall become
            the owner of such an invention (“SBAG

            Intellectual Property”) and shall grant IVN the non-exclusive,
            royalty-free right to use this invention solely for production of
            Fel d1 Fusion Protein, including all derivatives and other modifications.
          

        
	
          The parties undertake to mutually inform each other
            without delay of all inventions made in connection with the development
            of the production process of Fel d1 Fusion Protein, irrespective of
            whether such inventions are deemed patentable or not. It is understood
            between the parties that for inventions owned jointly by the parties
            either contracting party may file a patent application based on such
            invention only upon the prior written approval of the respective other
            contracting party provided that such approval shall not be unreasonably
            withheld. 

        
	
          In case that a remuneration according to Arbeitnehmererfinder-Gesetz
            is payable this remuneration has to be borne by the party which has
            been granted the patent. 

        
	
          In order to comply with theses principles, each party
            is obliged to execute all declarations in due form which is required
            therefore. Moreover, each party is obliged to assign any rights on
            inventions in accordance with these principles free of any third parties’
            rights. 

        

	 	 

	9.2 	
      All documentation and data produced in the context of
      carrying out the Fel d1 Fusion Protein process development will become the
      sole property of IVN, unless provided differently in this Article. Upon
      request SBAG shall provide these documents to IVN. Original documents that
      need to be retained by SBAG for regulatory purposes will be made available
      to IVN in form of copies.

	 	 
		
      IVN may decide upon its sole discretion to provide access
      to such documentation and data to regulatory authorities, to its licensees
      or to any other third party.

	 	 
	10 	
      Inspections

	 	 
		
      Representatives of IVN may, upon reasonable notice and at
      times acceptable to SBAG visit the facilities where the Fel d1 MAT Fusion
      Protein process is being performed, as well as audit all original
      documentation on site pertinent to the GMP manufacture and analytical
      testing.

10

	
11. 		
Duration and Termination of Agreement

	
	 	 
	
11.1 		
This Agreement shall become effective as of [] and shall remain in full force and effect until the obligations of the Parties hereunder have been fully performed, unless extended by mutual written agreement of the Parties.

	
	 	 
	
11.2 		
This Agreement may be terminated immediately (i) by SBAG as the case may be, upon material breach of this Agreement by IVN and the failure of IVN to cure such breach within thirty (30) days of receipt of SBAG`s written notice
describing such breach in reasonable detail or (ii) by IVN upon material breach of the Agreement by SBAG, and the failure of SBAG to cure such breach within thirty (30) days of receipt of IVN’s written notice describing such breach in
reasonable detail.

	
	 	 
	
11.3 		
In case of termination IVN shall pay all accrued costs arisen by performance of the services up to the termination date.

	
	 	 
	
11.4 		
This Agreement may be terminated by IVN giving two months notice in writing without giving reason provided IVN pays SBAG a lumpsum indemnification of Euro 60,000 (Euro sixty thousand) for keeping and having kept GMP slots in
reserve for IVN. In addition, Article 11.3 applies accordingly.

	
	 	 
	
11.5 		
The provisions of Articles 7, 8, 10 and 11, shall survive the termination of the Agreement. Upon termination of this Agreement each Party shall return to the other Party, or at the request of the other Party destroy, Confidential
Information of the other Party. Section 9 shall survive termination of this Agreement, except that the license of IVN shall terminate if SBAG terminates this Agreement for material breach of IVN or if IVN terminates this Agreement without reason
pursuant to Section 11.4.

	
	 	 
	
12. 		
Governing law

	
	 	 
	
12.1 		
This agreement shall be governed by the law of Germany.

	
	 	 
	
12.2 		
Place of jurisdiction is Hamburg

	
	 	 
	
13. 		
Miscellaneous Provisions

	
	 	 
	
13.1 		
Entirety of Agreement. This Agreement, together with the enclosed Appendix 1, Appendix 2, Appendix3 and Appendix 4 which constitute an integral part of this Agreement, is the entire and complete
understanding between the parties with respect to the subject matter hereof and supersedes and merges all prior or

	

11 

		
      contemporaneous proposals, discussions, negotiations,
      understandings, promises, representations, conditions, communications and
      agreements, whether written or oral, between the parties with respect to
      such subject matter and all past courses of dealing or industry
    custom.

	 	 
	13.2 	
      Amendments. No amendments, changes, modifications or
      alterations of the terms and conditions of the Agreement shall be binding
      upon either party hereto unless in writing and signed by both
    parties.

	 	 
	13.3 	
      Notices. All notices, demands, requests, or other
      communications which may be or are required to be given, served, or sent
      by any party to any other party pursuant to this Agreement shall be given
      in writing and in the English language by registered mail, internationally
      recognized overnight courier, fax (with confirmation of receipt) or by
      e-mail (to be confirmed in writing by registered mail in matters other
      than routine administrative matters) addressed to the addresses mentioned
      in the beginning of this Agreement and to the attention of the following
      persons:

	If to IVN 	If to SBAG 

	Dr. Martin Steiner 
ImVisioN GmbH 
Feodor-Lynen
      Straße 5 
D-30625 Hannover 
Germany 

Phone:
      +49-511-538-896-76 
Fax:: +49-511-538-896-66
      

m.steiner@imvision-therapeutics.com 	Dr. Bert Behnke 
Strathmann Biotec AG
      
Habichthorst 30 
D- 22459 Hamburg 
Germany 

Phone:
      +49-40-55905-815 
Fax: +49-40-55905-888
      

bert.behnke@strathmann.de 

	13.4 	
      If any provision of this AGREEMENT is held to be invalid
      or unenforceable all other provisions shall continue in full force and
      effect. The parties hereby agree to attempt to substitute for any invalid
      or unenforceable provision a valid or enforceable provision which achieves
      to the greatest and possible extent the economic, legal and commercial
      objectives of the invalid or unenforceable
provision.

	Hannover, August 22, 2005 	 	Hamburg, August 19, 2005 
	  	 	  
	/s/ Martin Steiner, Geschäftsführer/CEO 	 	./s/ Silke Strathmann, Vorstand 
	/s/ Horst Rose,
      Geschäftsführer/COO 	 	/s/
      Bert Behnke, Vorstand 

12

	ImVisioN GmbH 	Strathmann Biotec AG 

13

Appendix 1: Testing methods and Specifications of
Cellbanks

	 	Method 	Specification 
		  	  
	A. Identity 	 	 
		 	 
	Phenotye characterisation 	API20E 	conform with host strain 
	 	 	 
	Viability 	Plating assay 	             
         >1x107 cfu/ml 
	 	 	 
	Sequence Identity 	Restriction map 	             
         specific pattern 
	  	Sequencing (insert)* 	  
	B. Purity 	  	  
	 	 	 
	Microbial contamination 	Plating on complex media 	             
         absence of microbial 
	  	and selective media 	             
         contaminations 
	  	Microscopy (incl. Gram staining) 	 
	 	 	 
	Bacteriophages 	Plaque assay 	             
         absence of 
	  	  	             
         Bacteriophages 
	C. Stability 	  	  
	 	 	 
	Plasmid stability 	Replica plating 	  

* Double stranded Sequencing is performed under non GMP
conditions.

14

Appendix II: Analytical Testing methods for Fel d1 Fusion
Protein

	Methode 	  	Durchführung 
	1. Appearance 	  	  
	- Color 	Ph.Eur. 	SBAG 
	- Clarity 	Ph.Eur 	SBAG 
	2. pH 	  	SBAG 
	3. Protein content 	  	  
	- RP HPLC ? 	  	SBAG 
	4. Identification 	  	  
	- SDS-PAGE 	  	SBAG 
	- Peptide Mapping 	  	IVN 
	- N-terminal Sequencing 	  	IVN 
	- Western Blot 	  	SBAG 
	5. Purity 	  	  
	- SDS-PAGE 	  	SBAG 
	- RP HPLC 	  	SBAG 
	6. Impurity 	  	  
	- Total DNA 	  	SBAG 
	- Endotoxin 	Ph.Eur 	Extern (L&S) 
	7. Sterility 	Ph.Eur 	Extern (L&S)

15

Appendix III: Definition of Milestones

	1. Strain development completed: 	15.000,- EUR 
	 	 
	An E.coli strain for manufacturing of Fel d1 MAT
      Fusion Protein established and 
	accepted by IVN. Strain Development Report
      completed. 
	 
	2. Fermentation process developed: 	125.000,- EUR 
	 	 
	A fermentation process for expression of Fel d1
      MAT Fusion Protein developed. 
	Fermentation development report completed.
      Actually performed fermentations will 
	be invoiced at 12.500 EUR per fermentation. 	  
	 	 
	3. Refolding strategy developed: 	72.000,- EUR 
	 	 
	A process for primary recovery of inclusionbodies
      and refolding of Fel d1 MAT 
	Fusion Protein was developed. Development report
      completed. Actually required 
	working hours are invoiced at 150 EUR per hour. 	  
	 	 
	4. DSP development completed: 	192.000,- EUR 
	 	 
	A process for purification of Fel d1 MAT Fusion
      Protein was developed. 
	Development report completed. Actually required
      working hours are invoiced at 160 
	EUR per hour. 	  
	 	 
	5. Cellbanks established 	30.000,- EUR 
	 	 
	200 vials of MCB and 200 vials of WCB
      manufactured, tested and released. 
	Documentation consisting of manufacturing
      records, C of As and Quality report 
	completed. 	  
	 	 
	6. Tech Transfer completed: 	35.000,- EUR 
	 	 
	Process for manufacturing of Fel d1 MAT Fusion
      Protein was transferred to SBAG’s 
	Hannover GMP facility. Tech Transfer report completed. 	  
	 	 
	7. ‘Consistency’ runs completed 	49.000,- EUR 
	 	 
	Reproducibility demonstrated by one run. If one
      run is not sufficient and IVN orders 
	additional consistency runs, these shall be
      separately invoiced at € 49.000 each. 
	 
	8. GMP manufacturing completed 	120.000,- EUR 
	 	 
	Fel d1 MAT Fusion Protein was manufactured,
      tested and released. Protein shipped 
	to IVN or filling company. Documentation
      consisting of C of A and manufacturing 
	batch record is completed. 	  

16

	9. Analytical testing established 	80.000,- EUR 
	  	  
	Testing methods for RP HPLC, SDS-PAGE, Western
      Blotting and total DNA by 
	Threshold established. Testing instructions
      completed. Suitable subcontractors for 
	Endotoxin, Sterility, Peptide Mapping and
      N-terminal sequencing identified and 
	inspected. 	  

17

Appendix IV: Delimination of responsibilities

  	AREA OF RESPONSIBILITY 
	CUSTOMER 

        IVN 	Strathmann 

        Biotec AG 	Filling 

	1. Starting materials 	  	  	  
	1.1. Production strain 	  	  	  
	               
         Providing of Productionstrain 	  	X 	  
	               
         Identity 	  	X 	  
	               
         Determination Biosafety Level 	X 	  	  
	1.2 Other starting materials 	  	  	  
	               
         Supply/Procurement 	  	X 	  
	               
         QC Testing and Release 	  	X 	  
	               
         Retain samples 	  	X 	  
	1.3. Primary packaging materials (vial/ampoule) 	  	  	  
	               
         Supply/Procurement 	  	  	X 
	               
         QC Testing and Release 	  	X 	  
	               
         Retain samples 	  	  	X 
	1.4. Secondary packaging materials 	  	  	  
	               
         Supply/Procurement 	  	  	X 
	               
         QC Testing and Release 	  	  	X 
	               
         Retain samples 	  	  	X 
	2. Production 	  	  	  
	               
         Manufacturing instructions approved by 	  	X 	  
	               
         Manufacturing of Bulk Product and In-Process-Controls 	  	X 	  
	                
        Primary Packaging incl. In-Process-Controls 	 	X	   
	                
        Labeling 	X	 	 
	               
         Retain samples of Bulk Product 	  	X 	  
	               
         Retain samples of primary packaged Bulk Product	  	X 	  
	               
         Retain samples of Finished Product 	  	X 	  
	3. Quality Control 	  	  	  
	                
        QC testing of the primary packaged Bulk Product 	   	X 	   
	               
         Release for Shipment 	  	X 	  
	                
        Release of Finished Product for the use in clinical trials 	X	 	 
	               
         Stability testing 	X 	  	  

18Filed by Automated Filing Services Inc. (604) 609-0244 - Imvision Therapeutic Inc. - Exhibit 10.8

EXHIBIT 10.8 

Service Agreement

between

ImVisioN GmbH
Feodor-Lynen-Strasse
5, D-30625 Hanover 

- ImVisioN -

and

Digilab BioVisioN
GmbH
Feodor-Lynen-Strasse 5, D-30625 Hanover

- DBVN -

Introduction

ImVisioN runs its business on the
premises of the current main office of DBVN. In return for remuneration, DBVN
provides premises and staff infrastructure for this purpose within the framework
described in the following, and can provide further services on request.

In this connection, the parties agree
to the following:

	1 	
      Subject of the agreement

	 	 	 
	1. 	
      In return for payment of the remuneration agreed upon in
      clause 6, DBVN is obligated to

	 	 	 
		a) 	
      supply premises (clause 2);

		b) 	
      supply personnel (clause 3);

		c) 	
      provide services within the area of IT (clause 4)
    and

		d) 	
      provide other services to be agreed upon at any time
      (clause 5).

	 	 	 
		
      The services mentioned in clauses 2-4 are described by
      the parties as „fixed services“, and the services mentioned in clause 5
      are called „variable services“.

	 	 	 
	2. 	
      The extent of the before-mentioned services covered by
      the remuneration appear in detail on the basis of monthly services from
      the quantity outline attached in

– App. 1 –

		
      Services that go beyond this outline because of
      foundation or extent are subject to individual agreements. They are
      arranged through an offer from DBVN and an order from ImVisioN. The
      regulations of this service agreement also apply to these services, also
      when not men- tioned specifically.

	 	 
	3. 	
      If the amounts calculated for fixed services
      (clauses 2, 3 and 4) in the quantity outline should no longer be
      necessary to that extent in the duration of this agreement, adjustment of
      the quantity outline with up to +/- 50% is possible at one month’s notice
      from the announcement of the adjustment until it comes into force, yet not
      until three months after this agreement has come into force. More
      extensive changes require termination and renegotiation of the con-
      tract.

	 	 
	4. 	
      From the time that the adjustment comes into force, the
      remuneration according to the ad- justment of the quantity outline is to
      be paid.

1

 

	§ 2 	 Supply of premises 

      
	  	  
	  

	1. 	 At the main office of DBVN,
        DBVN supplies fully equipped offices and laboratories for Im- VisioN.
        This includes (listed in detail in ENCL. 1): 

	  	  
	  

	  	 - 
	 supply of premises, 

	  	 - 
	 supply of inventory, 

	  	 - 
	 supply of laboratory equipment, 

	  	 - 
	 supply of communication equipment (telephone,
        Internet, fax), 

		 - 
	 supply of IT hardware (PC, network, printer,
        etc.) incl. current Office software (how- ever, cf. section § 4),
      

	  	 - 
	 supply of materials for office use, 

	  	 - 
	 co-use of colour printers, copy machines,
        scanners, 

	  	 - 
	 co-use of seminar and meeting rooms as per
        agreement, 

	  	 - 
	 co-use of common rooms, 

	  	 - 
	 co-use of archive rooms. 

	  	  
	  

	2. 	
      The supply includes technical
        equipment to the extent that it is used by DBVN. Equipment beyond this
        standard requires special agreement. Replacement of equipment only occurs
        in case of malfunction. 

	  	  

       

	3. 	
      If the laboratories used by
        ImVisioN are run as S1 laboratories, ImVisioN has the sole re-
        sponsibility for correct notification and regulatory operation of these
        laboratories. 

	  	  

       

	§ 3 	
      Supply of secretary service
      

	  	  

       

	1. 	
      DBVN constantly supplies work
        capacity for secretary work from its own staff to the extent determined
        in the quantity outline 

	  	  

       

	2. 	
      The selection of employees for
        the above-mentioned services is subject to the assessment of DBVN. If
        DBVN does not have the appropriate staff capacity to the extent necessary,
        DBVN can terminate the agreement with regard to these services at one
        month’s notice. 

	  	  

       

	§ 4 	
      Services within the area
        of IT 

	  	  

       

	1. 	
      DBVN makes the software used
        by DBVN in the network used by DBVN available for ImVi- sioN. This mainly
        includes standard software in the area of office communication (MS-Office,
        etc.). Carrying out updates of this software is subject to the judgment
        of DBVN; therefore, ImVisioN is not entitled to specific software or a
        specific or new software version. 

	  	  

       

	2. 	
      Within the scope of its own
        business, DBVN maintains the functionality of the supplied soft- ware
        as well as possible. Any further work on the software requires previous
        acceptance from DBVN and is charged to ImVisioN. ImVisioN is not entitled
        to specific access to the soft- ware. 

	  	  

       

	3. 	
      The services include data security
        to the extent that DBVN carries out data security. 

	  	  

       

	4. 	
      The service also includes continuous
        maintenance of a web page for ImVisioN. This does not include any external
        costs connected with this. 

	  	  

       

	§ 5 	
      Variable services 

	  	  

       

		
      A pre-planning time of 4 weeks
        is agreed upon for the services listed below, in order for both parties
        to be able to adjust their work to the supply times agreed upon in the
        pre-planning: 

	  	
       
	  

	  	
      - 
	 Project management 

2

 

	  	 - 
	 HPLC service 

	  	 - 
	 Handling of patents 

	  	 - 
	 Expertise with regard to production
        and molecular biology 

		 The persons that are to provide
        the variable services may only be exchanged with the consent of both parties.
      

	  	  

       

	  	 Any entitlement to these services
        is subject to express confirmation from DBVN. 

	  	  

       

	§ 6 	 Remuneration 

	  	  

       

	1. 	 For fixed services, in
        accordance with clauses 2, 3 and 4, DBVN receives a standard amount of
        8,500 EUR (eight thousand five hundred) net to be paid every month in
        advance. These services do not result in a later document for receipt.
      

	  	  

       

	2. 	 For variable services,
        in accordance with clause 5, DBVN receives remuneration in accor- dance
        with the net hourly rates stated in APPENDIX 1. These services are paid
        on a monthly basis and are payable 10 days after invoicing. 

	  	  

       

	§ 7 	 Confidentiality 

	  	  

       

	1. 	 In the duration of this agreement
        and beyond the termination of the agreement, the parties are obligated
        to keep any technical information or business information that they have
        ac- quired before and during this agreement confidential, also when the
        information has not been speci- fied as specifically secret or confidential.
      

	  	  

       

	2. 	 The parties to this agreement
        are also to make sure that confidential information is not passed on by
        any third party that works with or for the party in question. 

	  	  

       

	3. 	 If a party becomes aware that
        confidential documents, business or operational secrets are published
        through the know-how of a third party or if a third party fails to keep
        documents confidential, this party is to inform the other party about
        this without delay. 

	  

       

	4. 	 Punishable violation of the
        before-mentioned obligations of confidentiality results in a con- tractual
        penalty for the violating party of 15,000 Euro for each violation, from
        which any other contractual penalties under this agreement are not subtracted.
        Any further legal claims for damages are not affected by the contractual
        penalties. 

	  	  

       

	§ 8 	 Liability 

	  	  

       

		 The parties limit the liability
        under this agreement to matters caused by intentional or grossly negligent
        conduct. 

	  	  

       

	§ 9 	 Duration of the agreement
      

	  	  

       

	1. 	 This agreement comes into force
        with retrospective effect from the 1st of February 2006 and
        is terminable at 3 months’ notice to the end of a quarter. The costs
        mentioned in Appendix 1 for the second floor will not be charged until
        from the 1st of April 2006. 

	  	  

       

	2. 	 A party’s right to extraordinary
        termination for an important reason because of violation of the agreement
        or similar occurrences is not changed. More specifically, it is considered
        an important reason for termination of the contract when a party to this
        agreement intentionally or negligently causes harm and the results of
        this are not eliminated within 30 days on de- mand. 

3

	§ 10 	Other stipulations, choice of
      court and venue 
	  	
      

	1. 	
      Apart from the arrangements stated in this agreement,
      there are no other arrangements be- tween the parties. Any further
      arrangements are hereby rendered irrelevant. Other arrange- ments,
      extensions and changes to this agreement only apply when in writing. This
      also applies to cancellation of this clause about the requirement of
      information in writing. 

	  	
      

	2. 	
      German legislation applies to all matters regarding this
      agreement. The venue of all disputes with regard to this agreement is
      Hanover. 

	  	
      

	§ 11 	
      Escape clause 

	  	
      

	1. 	
      If current or future stipulations in this contract are
      not legal or practicable or later lose their legality or practicability,
      totally or partly, the validity of the other stipulations in this agree-
      ment is not affected. This also applies if it turns out that the agreement
      contains deficiencies. 

	  	
      

	2. 	
      Instead of the ineffective or impracticable stipulation
      or for completion of the deficiency, a suitable arrangement should apply
      that the parties would have agreed upon if they had thought of the matter
      at the entering into the agreement. This also applies when the
      ineffectiveness af- fects the extent of a service or time limit stated in
      this agreement; in such cases, the agreed service or time limit is
      replaced by the closest possible legal extent of the service or time
      limit. 

	  	
      

	3. 	
      If the effect of a stipulation in accordance with the
      above can only be achieved through agreement on and with consideration for
      particular formal provisions, the parties will be obli- gated to carry out
      the required actions and give the necessary statements.

	Dusseldorf, the 31/3/05
	 	  
	 	 	 
	ImVisioN GmbH 
	 	  
	 	 	 
	/s/ Martin Steiner 	 	/s/ Horst Rose 
	Geschäftsführer/CEO 	 	Geschäftsführer/COO 
	  	 	  
	 Hannover, the 30/3/05

      
	 	  
	 	 	 
	Digilab BioVisioN GmbH 
	 	  
	 	 	 
	/s/ Wolfram Rodatz 	 	  
	Managing Director
      	 	  

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]